The Comparative Effects of Mesenchymal Stem Cell Transplantation Therapy for Spinal Cord Injury in Humans and Animal Models: A Systematic Review and Meta-Analysis

Simple Summary The effects of mesenchymal stem cell (MSC) transplants on functional recovery after spinal cord injury have been compared in humans and animal models. Data show that MSC transplants increase functional outcomes across species. However, modes and timings of MSC delivery mean that the animal studies cannot be used to predict outcome, suggesting that alternative models are required to improve translation of research to clinical trial. Animal models have been used in preclinical research to examine potential new treatments for spinal cord injury (SCI), including mesenchymal stem cell (MSC) transplantation. MSC transplants have been studied in early human trials. Whether the animal models represent the human studies is unclear. This systematic review and meta-analysis has examined the effects of MSC transplants in human and animal studies. Following searches of PubMed, Clinical Trials and the Cochrane Library, published papers were screened, and data were extracted and analysed. MSC transplantation was associated with significantly improved motor and sensory function in humans, and significantly increased locomotor function in animals. However, there are discrepancies between the studies of human participants and animal models, including timing of MSC transplant post-injury and source of MSCs. Additionally, difficulty in the comparison of functional outcome measures across species limits the predictive nature of the animal research. These findings have been summarised, and recommendations for further research are discussed to better enable the translation of animal models to MSC-based human clinical therapy.

Automated summary

The effects of mesenchymal stem cell transplants on functional recovery after spinal cord injury have been compared between humans and animal models. While MSC transplants show improved outcomes in both species, differences in delivery modes and timings suggest the need for alternative models to improve translation to clinical trials. Discrepancies in timing of MSC transplant post-injury and source of MSCs between human studies and animal models limit the predictive nature of the research. Further research and recommendations are needed to enhance translation of animal models to MSC-based human clinical therapy.